Report Library
All Reports
Datamonitor Asthma and COPD KOL Interview
February 29, 2016
Datamonitor interviewed a pulmonologist based in Boston, MA to determine their current treatment practices and opinions on
late-stage pipeline drugs for the treatment of COPD and asthma.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
Highlights
For our disclosures, please read the BioMedTracker Research Standards.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
Highlights
- KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.
- He likes simpler drugs for COPD patients for compliance reasons. Once a day is best and three times is just too much.
- He prescribes more LABA/LAMA drugs earlier than Gold Guidelines; doesn’t adhere to them strictly but teaches them.
- KOL says that Respimat is a very good aerosol device, but he generally prefers the dry powder devices (Boehringer).
- He would generally start COPD patients on Breo Ellipta over Advair if insurance will pay for it (GSK).
- Spiriva has been a good drug, and it will be hard to displace without some specific advantage (Boehringer).
- Physicians are skeptical of PDE4 drug, Daliresp, and people are going with theophyllines despite slightly worse side effect profile (AZN).
- KOL does not believe approval for Spiriva for asthma will change his use. He’s been using it off-label for a long time (Boehringer).
- He uses Xolair to treat asthma and thinks it is safe. The malignancy risks have been largely disproven (Roche).
- KOL does not believe that IL-5 inhibitors will be a panacea in asthma patients and will only be used in a small subset of patients (GSK, AZN).
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Respiratory |
Additional Resources: